Back to top
more

Akari Therapeutics (AKTX)

(Delayed Data from NSDQ)

$2.24 USD

2.24
8,487

+0.03 (1.36%)

Updated Oct 18, 2024 03:39 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Tenet Healthcare (THC) in Focus: Stock Moves 8.5% Higher

Tenet Healthcare (THC) shares rose nearly 9% in the last trading session, amid huge volumes.

    Alexion (ALXN) in Focus: Stock Moves 7.2% Higher

    Alexion (ALXN) shares rose more than 7% in the last trading session, amid huge volumes.

      Why AveXis (AVXS) Could Be Positioned for a Slump

      AveXis (AVXS) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

        ANI Pharmaceuticals (ANIP) Catches Eye: Stock Jumps 17.7%

        ANI Pharmaceuticals (ANIP) shares rose nearly 18% in the last trading session, amid huge volumes.

          Werner Enterprises, Cott, Akari Therapeutics, and Alexion highlighted as Zacks Bull and Bear of the Day

          Werner Enterprises, Cott, Akari Therapeutics, and Alexion highlighted as Zacks Bull and Bear of the Day

            Madeleine Johnson headshot

            Akari Therapeutics (AKTX) Stock is Skyrocketing Over 60% Today: Here's Why

            On Thursday, shares of biopharmaceutical company Akari Therapeutics (AKTX) are skyrocketing, up over 60% in midday trading--the stock was up 90% in premarket trading--after it announced it would advance its lead drug candidate.

              Idera Pharmaceuticals (IDRA) Jumps: Stock Rises 14.4%

              Idera Pharmaceuticals (IDRA) shares rose more than 14% in the last trading session, amid huge volumes.

                NewLink Genetics (NLNK) Jumps: Stock Rises 29.9%

                NewLink Genetics (NLNK) shares rose nearly 30% in the last trading session, amid huge volumes.

                  Athersys (ATHX) in Focus: Stock Moves 10.22% Higher

                  Athersys (ATHX) was a big mover last session, as the company saw its shares rise more than 10% on the day.

                    Regenxbio (RGNX) in Focus: Stock Moves 9.5% Higher

                    Regenxbio (RGNX) was a big mover last session, as the company saw its shares rise more than 9% on the day.

                      BioMarin (BMRN) in Focus: Stock Moves 5.6% Higher

                      BioMarin (BMRN) shares rose nearly 6% in the last trading session, amid huge volumes.

                        Cellectis (CLLS) Catches Eye: Stock Jumps 17%

                        Cellectis (CLLS) shares rose 17% in the last trading session, amid huge volumes.

                          Amgen Evenity Approval Derailed on Cardiovascular Side Effect

                          A late-stage study at Amgen, Inc. (AMGN) showed that its pipeline candidate Evenity/romosozumab led to a statistically significant superior fracture risk reduction.

                            What Falling Estimates & Price Mean for AveXis, Inc. (AVXS)

                            It seems wise to sell the AveXis, Inc. (AVXS) stock at this moment as its both estimates and price have been witnessing downward revision.

                              BioDelivery Sciences International (BDSI) Jumps: Stock Up 5%

                              BioDelivery Sciences International, Inc. (BDSI) shares rose over 5% in the last trading session.

                                Why Is Vertex Pharma (VRTX) Stock Soaring This Year?

                                Vertex Pharmaceuticals, Inc.'s (VRTX) shares have risen 57.8% this year so far, outperforming the increase of 1.3% for the Zacks classified Large-Cap Pharma industry.

                                  Biogen (BIIB) Buys Stroke Candidate Cirara for $120M

                                  Biogen Inc. (BIIB) announced the acquisition of Remedy Pharmaceuticals' phase III candidate, Cirara for the treatment of large hemispheric stroke (LHI).

                                    Geron Corp (GERN) Worth a Look: Stock Adds 7% in Session

                                    Geron Corporation (GERN) shares rose over 7% in the last trading session.

                                      Brian Hamilton headshot

                                      Bear of the Day: AMAG Pharmaceuticals (AMAG)

                                      Licensing expenses, increased SG&A, and limited market share expansion are weighing this stock down.

                                        Puma (PBYI) Q1 Loss Narrows, Focus Remains on Neratinib

                                        Puma Biotechnology, Inc. (PBYI) reported a first-quarter 2017 loss of $1.97 per share, narrower than the Zacks Consensus Estimate of a loss of $2.08 and the year-ago loss of $2.19.

                                          Celldex (CLDX) Q1 Loss In Line, Revenues Beat, Shares Up

                                          Celldex Therapeutics, Inc. (CLDX) posted first-quarter 2017 loss of 28 cents per share, which was in line with the Zacks Consensus Estimate

                                            Geron (GERN) Q1 Loss In Line, Focus Remains on Imetelstat

                                            Geron Corporation (GERN) reported a loss of 5 cents per share in the first quarter of 2017, in line with the Zacks Consensus Estimate. In the year-ago quarter.

                                              Clovis (CLVS) Q1 Loss Narrows, Rubraca Off to a Good Start

                                              Clovis Oncology, Inc. (CLVS) reported first-quarter 2017 loss of $1.33 per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.43 as well as the year-ago loss of $2.17 per share.

                                                Akari Therapeutics (AKTX) Shares March Higher, Can It Continue?

                                                As of late, it has definitely been a great time to be an investor in Akari Therapeutics PLC (AKTX).

                                                  Will Akari Therapeutics (AKTX) Continue to Surge Higher?

                                                  As of late, it has definitely been a great time to be an investor in Akari Therapeutics PLC (AKTX).